Since serum anti-Müllerian hormone (AMH) levels enable quantitative evaluation of ovarian damage, we conducted a computer-based search, using key words, of all articles published in English through the PubMed database from inception until September 2013 to summarize available studies evaluating ovarian reserve after ovarian toxic interventions to discuss the usefulness of serum AMH levels. We found that most of the studies demonstrated a decline in serum AMH levels when compared to control or pretreatment levels, with levels dependent on the type of treatment modality. Measurement of serum AMH levels enables quantitative evaluation of ovarian damage caused by ovarian toxic interventions, such as chemotherapy and radiotherapy, instead of qualitative evaluation using menstrual condition or basal follicle-stimulating hormone levels. Serum AMH levels are becoming indispensable to assess the ovarian reserve of patients who desire preservation of ovarian function for fertility and endogenous sex steroid hormones.
BroekmansFJKweeJHendriksDJMolBWLambalkCB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006;12
(6):685–718.
2.
BancsiLFBroekmansFJMolBWHabbemaJDte VeldeER. Performance of basal follicle-stimulating hormone in the prediction of poor ovarian response and failure to become pregnant after in vitro fertilization: a meta-analysis. Fertil Steril. 2003;79
(5):1091–1100.
3.
NelsonSM. Biomarkers of ovarian response: current and future applications. Fertil Steril. 2013;99
(4):963–969.
4.
LohJSMaheshwariA. Anti-Mullerian hormone—is it a crystal ball for predicting ovarian ageing?Hum Reprod. 2011;26
(11):2925–2932.
5.
DurlingerALGruijtersMJKramerP. Anti-Mullerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology. 2002;143
(3):1076–1084.
6.
WeenenCLavenJSVon BerghAR. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004;10
(2):77–83.
7.
AndersonRANelsonSMWallaceWH. Measuring anti-Mullerian hormone for the assessment of ovarian reserve: when and for whom is it indicated?Maturitas. 2012;71
(1):28–33.
8.
de VetALavenJSde JongFHThemmenAPFauserBC. Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril. 2002;77
(2):357–362.
9.
FanchinRSchonauerLMRighiniCGuibourdencheJFrydmanRTaiebJ. Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod. 2003;18
(2):323–327.
10.
van RooijIABroekmansFJSchefferGJ. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril. 2005;83
(4):979–987.
11.
La MarcaASighinolfiGRadiD. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010;16
(2):113–130.
12.
van DisseldorpJLambalkCBKweeJ. Comparison of inter- and intra-cycle variability of anti-Mullerian hormone and antral follicle counts. Hum Reprod. 2010;25
(1):221–227.
13.
StroupDFBerlinJAMortonSC. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283
(15):2008–2012.
14.
LeeSJSchoverLRPartridgeAH. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24
(18):2917–2931.
15.
McLarenJFBatesGW. Fertility preservation in women of reproductive age with cancer. Am J Obstet Gynecol. 2012;207
(6):455–462.
16.
LeeSOzkavukcuSHeytensEMoyFOktayK. Value of early referral to fertility preservation in young women with breast cancer. J Clin Oncol. 2010;28
(31):4683–4686.
17.
Lutchman SinghKMuttukrishnaSSteinRC. Predictors of ovarian reserve in young women with breast cancer. Br J Cancer. 2007;96
(12):1808–1816.
18.
PartridgeAHRuddyKJGelberS. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril. 2010;94
(2):638–644.
19.
SuHISammelMDGreenJ. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer. 2010;116
(3):592–599.
20.
AndersonRACameronDA. Pretreatment serum anti-mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab. 2011;96
(5):1336–1343.
21.
AndersonRAThemmenAPAl-QahtaniAGroomeNPCameronDA. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod. 2006;21
(10):2583–2592.
22.
AndersCMarcomPKPetersonB. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest. 2008;26
(3):286–295.
23.
SuHIFlattSWNatarajanLDeMicheleASteinerAZ. Impact of breast cancer on anti-Mullerian hormone levels in young women. Breast Cancer Res Treat. 2013;137
(2):571–577.
24.
LeeSOzkavukcuSHeytensEMoyFAlappatRMOktayK. Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone. J Assist Reprod Genet. 2011;28
(7):651–656.
25.
RosendahlMAndersenCYErnstE. Ovarian function after removal of an entire ovary for cryopreservation of pieces of cortex prior to gonadotoxic treatment: a follow-up study. Hum Reprod. 2008;23
(11):2475–2483.
26.
GiuseppeLAttilioGEdoardoDNLoredanaGCristinaLVincenzoL. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology. 2007;12
(2):141–147.
27.
van BeekRDvan den Heuvel-EibrinkMMLavenJS. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin’s lymphoma during childhood. J Clin Endocrinol Metab. 2007;92
(10):3869–3874.
28.
DecanterCMorschhauserFPignyPLefebvreCGalloCDewaillyD. Anti-Mullerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results. Reprod Biomed Online. 2010;20
(2):280–285.
29.
Lie FongSLugtenburgPJSchipperI. Anti-mullerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies. Hum Reprod. 2008;23
(3):674–678.
30.
LawrenzBFehmTvon WolffM. Reduced pretreatment ovarian reserve in premenopausal female patients with Hodgkin lymphoma or non-Hodgkin-lymphoma—evaluation by using antimullerian hormone and retrieved oocytes. Fertil Steril. 2012;98
(1):141–144.
31.
BathLEWallaceWHShawMPFitzpatrickCAndersonRA. Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound. Hum Reprod. 2003;18
(11):2368–2374.
32.
Lie FongSLavenJSHakvoort-CammelFG. Assessment of ovarian reserve in adult childhood cancer survivors using anti-Mullerian hormone. Hum Reprod. 2009;24
(4):982–990.
33.
van WaasMNeggersSJTe WinkelMLBeishuizenAPietersRvan den Heuvel-EibrinkMM. Endocrine late sequelae in long-term survivors of childhood non-Hodgkin lymphoma. Ann Oncol. 2012;23
(6):1626–1632.
34.
HamreHKiserudCERuudEThorsbyPMFossaSD. Gonadal function and parenthood 20 years after treatment for childhood lymphoma: a cross-sectional study. Pediatr Blood Cancer. 2012;59
(2):271–277.
35.
MorseHElfvingMLindgrenAWolner-HanssenPAndersenCYOraI. Acute onset of ovarian dysfunction in young females after start of cancer treatment. Pediatr Blood Cancer. 2013;60
(4):676–681.
36.
DillonKESammelMDPrewittM. Pretreatment antimullerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertil Steril. 2013;99
(2):477–483.
37.
GraciaCRSammelMDFreemanE. Impact of cancer therapies on ovarian reserve. Fertil Steril. 2012;97(1):134–140 e131.
38.
CunyATrivinCBrailly-TabardS. Inhibin B and anti-Mullerian hormone as markers of gonadal function after treatment for medulloblastoma or posterior fossa ependymoma during childhood. J Pediatr. 2011;158(6):1016–1022. e1011.
39.
IwaseASugitaAHirokawaW. Anti-Mullerian hormone as a marker of ovarian reserve in patients with ovarian malignancies who have undergone fertility-preserving surgery and chemotherapy. Gynecol Endocrinol. 2013;29
(4):357–360.
40.
IwaseASugitaAHirokawaW. Anti-Mullerian hormone as a marker of ovarian reserve following chemotherapy in patients with gestational trophoblastic neoplasia. Eur J Obstet Gynecol Reprod Biol. 2013;167
(2):194–198.
41.
MokCCChanPTToCH. Anti-mullerian hormone and ovarian reserve in systemic lupus erythematosus. Arthritis Rheum. 2013;65
(1):206–210.
42.
MorelNBachelotAChakhtouraZ. Study of anti-Mullerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide. J Clin Endocrinol Metab. 2013;98
(9):3785–3792.
43.
SmolenJSAletahaDBijlsmaJW. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69
(4):631–637.
44.
FrancoJGJrOliveiraJBPetersenCGMauriALBaruffiRCavagnaM. Adjuvant therapy with GnRH agonists/tamoxifen in breast cancer should be a good council for patients with hormone receptor-positive tumours and wish to preserve fertility. Med Hypotheses. 2012;78
(4):442–445.
45.
DieudonneASVandenbergheJGeertsI. Undetectable antimullerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor. Menopause. 2011;18
(7):821–824.
46.
JantkeARendtorffRDittrichR. Association between self-reported questionnaire data on fertility and results of hormone analyses in women after childhood cancer: a cross-sectional study. J Obstet Gynaecol Res. 2012;38
(10):1254–1259.
47.
BroughamMFCroftonPMJohnsonEJEvansNAndersonRAWallaceWH. Anti-Mullerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study. J Clin Endocrinol Metab. 2012;97
(6):2059–2067.
48.
BrouwerJLavenJSHazesJMSchipperIDolhainRJ. Levels of serum anti-Mullerian hormone, a marker for ovarian reserve, in women with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013;65(9):1534–1538.
49.
DominguesTSRochaAMSerafiniPC. Tests for ovarian reserve: reliability and utility. Curr Opin Obstet Gynecol. 2010;22
(4):271–276.
50.
LambalkCBvan DisseldorpJde KoningCHBroekmansFJ. Testing ovarian reserve to predict age at menopause. Maturitas. 2009;63
(4):280–291.
51.
LiHWNgEHWongBPAndersonRAHoPCYeungWS. Correlation between three assay systems for anti-Mullerian hormone (AMH) determination. J Assist Reprod Genet. 2012;29
(12):1443–1446.
52.
RustamovOSmithARobertsSA. The measurement of anti-Mullerian hormone: a critical appraisal. J Clin Endocrinol Metab. 2014;99
(3):723–732.
53.
DecanterCPeigneMMailliezA. Toward a better follow-up of ovarian recovery in young women after chemotherapy with a hypersensitive anti-Mullerian hormone assay. Fertil Steril. 2014;102
(2):483–487.
54.
SuHISammelMDHomerMVBuiKHaunschildCStanczykFZ. Comparability of antimullerian hormone levels among commercially available immunoassays. Fertil Steril. 2014;101(6):1766–1772.e1761.
55.
WelshPSmithKNelsonSM. A single-centre evaluation of two new anti-Mullerian hormone assays and comparison with the current clinical standard assay. Hum Reprod. 2014;29
(5):1035–1041.
SmithGDSerafiniPCFioravantiJ. Prospective randomized comparison of human oocyte cryopreservation with slow-rate freezing or vitrification. Fertil Steril. 2010;94
(6):2088–2095.
